Logo

American Heart Association

  2
  0


Final ID: Mo4148

Phenotypic clustering of right heart dilatation in pulmonary arterial hypertension

Abstract Body (Do not enter title and authors here):

Introduction
Right ventricular (RV) and right atrial (RA) dilatation are important hallmarks of disease severity in patients with pulmonary arterial hypertension (PAH). To obtain more insights on the clinical significance of RA dilatation, we phenotypically characterized patients with right heart dilatation.

Aim
Description of different RV/RA phenotypes in PAH

Methods
203 incident, treatment naïve PAH patients with cardiac magnetic resonance (CMR) imaging were included. Phenotypic clustering was based on RA and RV dilatation. Conform literature, RA dilatation was defined by a RA index maximal area >15 cm2/m2. RV dilatation was defined by an RVEDV/LVEDV ratio >1.3 and >2.4 for extreme dilatation.

Results
Four phenotypic patient clusters were identified: no dilatation (n=48), RV dilatation (n=78), RV+RA dilatation (n=53) and extreme RV dilatation + RA dilatation (n=23), Figure 1A. To unravel the additive clinical value of RA dilatation, we mainly compared patients with RV dilatation and patients with RV+RA dilatation. Intriguingly, patients with RV+RA dilatation demonstrated lower 3- and 5-year survival rates (58% and 43% vs. 75% and 55%) (Figure 1B) and were less likely to reverse RV dilatation after treatment initiation than patients with RV dilatation only. Despite the consequences of RA dilatation, we could not identify an explanation for the difference in RA dilatation between both groups. No difference in afterload was observed, shown by comparable pulmonary vascular resistance (9.9 [6.8-13] WU vs. 10 [7.5-12.3] WU, p>0.05). RV function was similarly impaired (RV ejection fraction: 36±9% vs. 33±9%, p>0.05). End-diastolic elastance (0.73 [0.39-1.11] mmHg/mL vs. 0.58 [0.40-0.94] mmHg/mL, p>0.05) and severity of tricuspid regurgitation did not differ. Finally, diuretic use (40% vs. 40%, p>0.05), age (54±16 vs. 57±19 yrs, p>0.05), female gender (70% vs. 60%, p>0.05) and iPAH diagnoses was similar (69% vs. 59%, p>0.05).

Conclusion
PAH-patients with both RA and RV dilatation have a worse clinical profile than patients with only RV dilatation. However, no clear trigger for RA dilatation was found and future mechanistic studies should unravel factors explaining these differences in right heart adaptation.
  • Celant, Lucas  ( Amsterdam UMC location Vrije Universiteit Amsterdam, PHEniX laboratory, Department of Pulmonary Medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Wessels, Jeroen  ( Amsterdam UMC location Vrije Universiteit Amsterdam, PHEniX laboratory, Department of Pulmonary Medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Meiboom, Lilian  ( Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Marcus, J. Tim  ( Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Bogaard, Harm  ( Amsterdam UMC location Vrije Universiteit Amsterdam, PHEniX laboratory, Department of Pulmonary Medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Strijkers, Gustav  ( Amsterdam UMC location University of Amsterdam, Department of Biomedical Engineering and Physics, Meibergdreef 9, , Amsterdam , Netherlands )
  • Handoko, M.  ( Universitair Medisch Centrum Utrecht, Department of Cardiology, Heidelberglaan 100 , Utrecht , Netherlands )
  • Vonk Noordegraaf, Anton  ( Amsterdam UMC location Vrije Universiteit Amsterdam, PHEniX laboratory, Department of Pulmonary Medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • De Man, Frances  ( Amsterdam UMC location Vrije Universiteit Amsterdam, PHEniX laboratory, Department of Pulmonary Medicine, De Boelelaan 1117 , Amsterdam , Netherlands )
  • Author Disclosures:
    Lucas Celant: DO NOT have relevant financial relationships | Jeroen Wessels: DO NOT have relevant financial relationships | lilian meiboom: DO NOT have relevant financial relationships | J. Tim Marcus: No Answer | Harm Bogaard: DO NOT have relevant financial relationships | Gustav Strijkers: No Answer | M. Handoko: DO have relevant financial relationships ; Speaker:AstraZeneca:Past (completed) ; Speaker:Boehringer-Ingelheim:Past (completed) ; Speaker:Abbott:Past (completed) ; Speaker:Novartis:Past (completed) | Anton Vonk Noordegraaf: No Answer | Frances De Man: DO have relevant financial relationships ; Research Funding (PI or named investigator):BIAL:Past (completed) ; Research Funding (PI or named investigator):Janssen:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Chasing the Clot: Managing Pulmonary Embolic Disease

Monday, 11/18/2024 , 01:30PM - 02:30PM

Abstract Poster Session

More abstracts from these authors:
BMP10 as novel marker for right atrial dilatation and pressure in precapillary pulmonary hypertension

Llucia-valldeperas Aida, Van Wezenbeek Jessie, Groeneveldt Joanne, Sanchez-duffhues Gonzalo, Vonk Noordegraaf Anton, Bogaard Harm, Goumans Marie Jose, De Man Frances

Effect Of A Bone Morphogenetic Protein Receptor Type 2 Mutation On The Cardiomyocyte Response To Pressure Overload

Llucia-valldeperas Aida, Van Wezenbeek Jessie, Smal Rowan, Bekedam Fjodor, Vonk Noordegraaf Anton, Bogaard Harm, De Man Frances

You have to be authorized to contact abstract author. Please, Login
Not Available